LEO Pharma Announces FDA Approval of Adbry™ (tralokinumab) as the First and Only Treatment Specifically Targeting IL-13 for Adults With Moderate-to-Severe Atopic Dermatitis December 28, 2021 by Businesswire [#item_full_content] Related Spread the word
English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Japanese
Portuguese
Russian
Spanish